Grants and Contributions:
Title:
Development of an orally-active antibiotic to treat antimicrobial resistant (AMR) bacterial infections
Agreement Number:
898980
Agreement Value:
$245,000.00
Agreement Date:
Apr 1, 2018 - Mar 31, 2020
Description:
Antimicrobial resistance bacteria (AMR) have a significant impact on mortality, hospital stay and associated costs. The overall objectives of the project are to prepare new oral antibiotics capable of killing AMR and treating serious and life-threatening infections in patients.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5H 0L9
Reference Number:
172-2018-2019-Q4-898980
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
822507489
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is -5,000 dollars.
Amendment Date
Feb 24, 2020
Recipient's Legal Name:
Fedora Pharmaceuticals Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: